One of the largest conventions in healthcare is coming to Philadelphia this month. BIO’s International Convention attracts Biotechnology buffs worldwide. This year, Global Genes is honored to accept BIO’s invitation to have our CEO and Founder, Nicole Boice, introduce key note speaker, Dr. Richard Peters, as well as participate in rare disease forums.

Dr. Peters leads the Global Rare Diseases Business Unit at Genzyme. He has been at the company for the past 7 years with prior roles as Head of Global & US Medical Affairs for the Genzyme Transplant & Oncology Division, Medical Officer for Sanofi Global Oncology, Strategy Development Officer for the US Rare Disease Genzyme organization, and Deputy Head for the Genzyme Global Rare Diseases Division. His prior roles in industry include medical leadership roles at Onyx Pharmaceuticals and Amgen, as well as Chief Executive Officer of Mednav, a venture capital-backed healthcare information technology start-up.

Dr. Peters also served on the clinical staff at Massachusetts General Hospital in Boston. He began his medical training at the Université Catholique de Louvain in Brussels, Belgium. After immigrating to the US, he earned his MD and PhD in Pharmacology from the Medical University of South Carolina and completed postgraduate training at Massachusetts General Hospital and held a Howard Hughes Medical Institute Fellowship at Harvard Medical School.

Dr. Peters also served as a consulting editor for JAMA and a contributing editor for Science, and has authored over 120 research articles and editorials. He serves on the Board of Directors of X4 Pharmaceuticals and the Scientific Advisory Board of Aura Biosciences, as well as is a Board member of the Massachusetts Outdoor Heritage Foundation. In his free time, he enjoys horseback riding and organic farming.

BIO’s International Convention will be host to multiple forums on Rare Disease.
The topics for these forums include:

  • Orphan & Rare Disease Track Opening Plenary: What is Rare?
  • The Power of Collaborations: Therapeutic Advances in Rare Diseases
  • Achieving Successful Marketing Authorizations for Orphan Products: Experience from Both Sides of the Atlantic
  • Small Patient Populations, Large Value Propositions: Defining and Differentiating the Value of Rare Disease Therapies
  • Orphan and Rare Diseases Track Reception

 

Learn more about BIO’s International Convention and topics to be covered during their forums June 15th-18th, here.

X